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α,β-Unsaturated acylimidazoles have been used in a plethora 
of enantioselective transformations over the years and have 
unsurprisingly become privileged building blocks for 
asymmetric catalysis. Interestingly however, their use in 
asymmetric biohybrid catalysis as bidentate substrates able 
to interact with artificial metalloenzymes has only recently 
emerged, expanding considerably in the last few years. Easy 
to prepare and to post-transform, α,β-unsaturated 
acylimidazoles appear as leading synthons for the 
asymmetric construction of C−C and C−O bonds. This 
Minireview highlights the current and increasing interest of 
these key building blocks in the context of asymmetric 
biohybrid catalysis with the aim to stimulate further research 
into their still unexploited potential. 
1. Introduction 
The conjugate addition of nucleophiles to electron-deficient 
alkenes is a common strategy for the formation of C−C and 
C−heteroatom bonds which dates back to the pioneering work 
of Komnenos in 1883[1] and Michael in 1887.[2] After more 
than a century of improvements devoted to the optimization of 
all the reaction parameters, catalytic asymmetric conjugate 
additions have become highly selective and, most importantly, 
highly reliable transformations leading to a broad range of 
optically active compounds with use in fields such as natural 
product synthesis and medicinal chemistry.[3] Over the years, 
it has been demonstrated that both organometallic and non-
organometallic nucleophiles could be involved.[4] This later 
class emerged in the early 80’s with the description of a 
diamine/Co(II) complex[5] and later by using chiral 
bisoxazoline type ligands[6] able to coordinate a variety of 
metals.[7] It soon emerged that bidentate substrates were 
ideally fitted to provide the necessary synergistic effect to 
reach high catalytic performance through an efficient 
coordination with the chiral metallic complex. Over the years, 
a number of α,β-unsaturated acyl derivatives (compounds 1-7, 
Figure 1) were evaluated in a variety of synthetic 
transformations including Michael and Mukaiyama-Michael 
type additions, Diels-Alder and hetero-Diels-Alder 
cycloadditions as well as Friedel-Crafts alkylations.[8–16] 
However, all the reactions involving the aforementioned 
substrates required cryogenic conditions to reach high levels 
of enantioselectivity ultimately limiting the scope. To 
overcome this drawback, Evans and co-workers introduced 
the use of α,β-unsaturated 2-acyl-imidazole 8 as a new 
bidentate substrate.[17] The latter showed an increased 
reactivity attributed to a lower steric demand and a higher 
electophilicity of the enone when compared to the 
α,β-unsaturated-acyl-pyrazoles 1, oxazolidinones 3, 
thiazolidine-2-thiones 4, phosphonates 5, benzimidazoles 9, 
thiazoles 10 and pyridines 11.[18] In addition, the chiral Lewis  
 
 
Figure 1. Enone commonly used in asymmetric catalysis (R1 = Alkyl, Aryl, 
R2 = Alkyl, R3 = Alkyl). 
 
acid-catalysed conjugate addition of various indoles in the 
presence of (PyBox)-Sc(III) led to the corresponding Friedel-
Crafts alkylation products with excellent levels of 
enantioselectivity. 
The synthesis of α,β-unsaturated 2-acyl-imidazoles is 
relatively trivial and usually relies on either the introduction of 
the imidazole ring on an α,β-unsaturated acyl precursor or on 
the formation of the double bond via some sort of olefination 
reaction (Figure 2). Okamoto et al. were, to the best of our 
knowledge, the first to 
describe the synthesis 
of α,β-unsaturated acyl 
imidazoles such as 8 
through the addition of 
the deprotonated 
N-methylimidazole 13 
onto α,β-unsaturated-N-
acyl-pyrrolidine 12 
(Figure 2).[19] Other 
syntheses involve the 
direct addition of the 
deprotonated form of 13 
on an α,β-unsaturated 
ester 14, a carboxylic 
acid 15, an acyl chloride 
16 or on a Weinreb 
amide 18. Similarly, the 
addition of 13 on an 
enal 17 followed by an 
oxidation of the 
resulting alcohol 
intermediate can also 
be envisioned.[20] 
Ultimately, a tandem 
aldol/crotonization 
between aldehyde 19 
and N-methyl-2-
acylimidazole 20[21,22] or 
a Wittig reaction with 
the appropriate 
phosphorous ylide 21[17] also leads to the title compound. 
Finally, the phosphorous ylide can be replaced by a 
phosphonate derivative such as 22, which can readily 
undergo a Horner-Wadsworth-Emmons type olefination.[23,24] 
In addition to improving catalytic performances, the 
imidazole moiety presents the advantage of being very 
versatile.  
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Figure 3. Post-transformation of the imidazole moiety. 
Indeed, compared to other bidentate enones such as the 
ones showcased in Figure 1, acyl imidazoles have the 
advantage of being readily convertible to the corresponding 
ketones, aldehydes,[25] amides, esters[26-28] or carboxylic acids 
through simple synthetic transformations (Figure 3a).[29] This 
particularity has notably been exploited in the synthesis of 
various natural products and natural product analogues such 
as (S)-ar-turmerone and an ionone derivative,[30] as well as in 
the synthesis of pyrrolidines,[31] β-hydroxy-β-aminoacids,[27] 
12-(S)-hydroxyeicosatetraenoic acid [12-(S)-HETE][32] and the 
alkaloid (+)-heliotridane (Figure 3b).[29] 
While the development of artificial metalloenzymes for 
asymmetric catalysis debuted in the 70s,[33-38] it is only 
recently that α,β-unsaturated-2-acyl-imidazoles have 
emerged as privileged scaffolds in biohybrid catalysis. It is 
indeed Scheidt and co-workers that first reported the use of 
α,β-unsaturated-2-acyl-imidazole 8.[22] In this seminal article, 
a conjugate addition of a carbonyl anion was performed in the 
presence of an N-heterocyclic carbene organo-catalyst (NHC) 
under physiological conditions, thus unveiling the possibility of 
using α,β-unsaturated-2-acyl-imidazoles in asymmetric 
biohybrid catalysis in general and DNA-based asymmetric 
catalysis in particular.  
2. DNA-based asymmetric catalysis  
2.1. Natural DNA-helix  
The concept of DNA-based asymmetric catalysis, first 
introduced by Roelfes and Feringa in 2005,[39] relies on a 
transfer of chirality from the DNA double helix to a pro-chiral 
substrate using an achiral transition metal catalyst[40] 
imbedded within the DNA scaffold (Figure 4). The resulting 
supramolecular architecture provides the necessary chiral 
microenvironment to induce sufficient enantiodiscrimination.  
 
Figure 4. DNA-based asymmetric Diels-Alder 
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Figure 5. DNA-based asymmetric Michael. 
This concept was initially tested on the Diels-Alder 
reaction between azachalcone 11 and cyclopentadiene 23 in 
the presence of commercially available DNA extracted from 
salmon testes (st-DNA). The first generation of ligands that 
were used were derived from the 9-aminoacridine intercalant, 
which was covalently bound to a Cu(II) binding diamine. High 
endo/exo selectivities were obtained (up to 98/2 in favour of 
the endo product) albeit moderate enantioselectivities (up to 
53% ee). Nonetheless, these results demonstrated that the 
DNA double helix could be used as a powerful source of 
chirality in the context of asymmetric catalysis.[41] 
A follow-up investigation evaluating the influence of the 
achiral ligand allowed Roelfes and co-workers to identify 
commercially available 4,4’-dimethyl-2,2’-bipyridine L3 as an 
efficient and simpler alternative to L1 and L2 leading to an 
almost complete endo selectivity (endo/exo = 99:1) and 
excellent enantioselectivities (99% and 98% ee at 30 and 
5 mol% catalyst loading respectively.[42] Interestingly, similar 
results were also obtained on β-aryl-substituted α,β-
unsaturated acyl imidazoles (Figure 4).[43] 
These results prompted Roelfes and co-workers to 
evaluate other C−C bond forming reactions in presence of 
DNA.[44] Hence, the addition of nitromethane or dimethyl 
malonate to 8 allowed the formation of the corresponding 
Michael addition products with ees up to 94% and 99%, 
respectively (Figure 5). 
Mechanistically, the formation of the major enantiomer 
was proposed to result from the Si face attack of the 
complexed acylimidazole substrate as shown in Figure 6. 
 
Figure 6. Schematic representation of the complexed acylimidazole 
substrate in DNA. 
The nature of the Michael donor was later extended to 
malonitrile by Li et al.[45] Hence, after a thorough screening of 
the reaction conditions, the use of L3/Cu(II) in conjunction 
with st-DNA was shown to afford excellent conversions and 
high levels of selectivity (up to 72% ee, Figure 7). 
Interestingly, the addition of dissymmetric cyanoacetate 
derivatives generated the two diastereoisomers in roughly the 
same ratio in up to 84% ee. 
 
Figure 7. DNA-based conjugate addition of malonitrile derivatives. 
Another benchmark in the field concerned the 
optimization of the enantioselective Friedel-Crafts alkylation 
with indoles.[46] Hence, through binding affinity studies, 
Roelfes and co-workers were able to show that only 16% of 
the catalyst was bound to DNA, while at the same time a 30-
fold rate enhancement could be observed when the reaction 
was run in the presence of DNA, thus suggesting that the 
background reaction was negligible. As a general trend, the 
reactions all led to full conversions and ees reaching up to 
83% (Figure 8).  
 
Figure 8. DNA-based asymmetric Friedel-Crafts alkylation. 
As a general trend, the best selectivities were obtained 
with substrates bearing an alkyl substituent at the β position 
of the enone. Most importantly, the authors were able to show 
that reaction was scalable and that the catalysts could be 
recycled without any noticeable loss of reactivity or selectivity. 
Finally, pyrroles were also shown to be compatible with ees 
reaching up to 76%. 
A few years later, Sugiyama et al. reported an 
intramolecular version of the Friedel-Crafts alkylation using 
the bifunctional acylimidazoles 36 (Figure 9).[47] The reactions 
catalysed by a st-DNA/5,6-dimethyl-1,10-phenanthroline 
L4/Cu(II) complex proved highly selective as up to 78% ee 
were obtained with a 5-methoxy group on the indole ring. In 
sharp contrast, substrates substituted on the nitrogen 
afforded much lower selectivities.  
 
Figure 9. DNA-based intramolecular Friedel-Crafts alkylation. 
The influence of the co-solvent in the Friedel-Crafts 
alkylation and the Michael addition was also evaluated.[48] It 
was notably shown that up to 10% v/v of acetonitrile in water 
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did not affect the binding constant of the catalyst to DNA 
while allowing an efficient scale-up of the reactions. 
Furthermore, an acceleration rate of the reaction was noted 
and attributed to a fast dissociation constant of the product. 
The catalytic enantioselective oxa-Michael addition was 
also reported by Roelfes and co-workers with up to 86% ee 
(Figure 10).[49] In these experiments, methanol but also 
ethanol and isopropanol were used in 40% v/v, however the 
conversions dropped when increasing the size of the alkyl 
group at the β-position of the enone, while no reactivity was 
observed with β-aromatic substituents. Also worth noting is 
the formation of the hydration side product in all cases, 
however this could be minimized by lowering the temperature 
to −18 °C. 
 
 
Figure 10. DNA-based asymmetric oxa-Michael addition. 
The first example of a non-enzymatic syn-hydration was 
reported by Roelfes and co-workers in 2010 using st-DNA in 
association with the same L2/Cu(II) metallic co-factor used for 
the oxa-Michael addition (Figure 11).[50] Under these 
conditions, α,β-unsaturated 2-acyl imidazoles could be readily 
converted to the corresponding β-hydroxy ketones in up to 
72% ee. In all these experiments, only the β-methyl 
substituted acyl imidazole led to full conversions albeit with 
low ees, while substrates bearing a β-t-butyl moiety led to 
higher ees but lower conversions. Surprisingly, replacing the 
methyl by an i-propyl group on the imidazole ring led to a 
racemic mixture of products, thus highlighting the impact of 
the steric hindrance induced by the substrate as well as the 
coordination sphere environment on the stereoselectivity of 
the reaction. 
 
Figure 11. DNA-based asymmetric syn-hydration.  
2.2 Synthetic DNA-helix  
2.2.1 Supramolecular approach 
 
The results obtained with natural DNA clearly highlight the 
importance of the binding between the metallic co-factor and 
the double helix. This prompted the community to next 
evaluate the influence of specific sequences on the reaction 
rate and ultimately on the enantioselectivity. A first set of 
experiments was run on the Diels-Alder cycloaddition 
between acylpyridine 11 (Figure 1) and cyclopentadiene 
using various L3/Cu(II)/DNA complexes.[51] While no apparent 
sequence-selectivity could be established, the GC rich 12 mer 
sequence d(TCAGGGCCCTGA)2, ODN1, led to slightly 
higher ees (99.4% ee) compared to st-DNA (98.5% ee). 
A similar study was performed on the Friedel-Crafts 
alkylation using this time α,β-unsaturated 2-acyl imidazole 8 
as a model substrate.[46] Similarly to the Diels-Alder 
cycloaddition, ODN1 led to usually higher ees and 
conversions than st-DNA, while AT-rich oligonucleotides were 
found to induce a decrease of ees. 
Interestingly, in the case of the intramolecular Friedel-
Crafts alkylation with 2-acyl imidazole 36 (Figure 9), 
Sugiyama and co-workers showed that AT-rich duplexes 
gave rise to higher enantioselectivities.[47] To understand 
these results a theoretical investigation was undertaken by 
modelling 28 conformations of ODN2 d(CAAAAATTTTTG)2 
with L4/Cu(II). The simulations revealed a higher binding 
energy of ODN2 toward the pro-(S) conformation of 
2-acylimidazole 36. Moreover, a shorter distance between the 
two carbons involved in the newly formed C−C bond was 
observed in the case of the pro-S complex more in line with 
the expected transitional state.[52]  
This sequence-selectivity was also evaluated in the case 
of the syn-hydration, where higher selectivities were obtained 
with sequences bearing an AT-rich central segment, however 
the structure of the ligand was also shown to be crucial.[53] 
Finally, in the case of the oxa-Michael addition, AT-rich 
ODN2 gave rise to higher ees [82% conv.; 43% ee] than the 
GC-rich sequence ODN1 [68% conv.; 19% ee] (Figure 11), 
albeit still lower than st-DNA.[49] 
These results prompted our group to devote our first 
efforts in the field of biohybrid catalysis toward the control of 
the enantioselective outcome. While many studies evaluated 
various parameters including the influence of the metallic co-
factor to selectively access one specific enantiomer, the 
inversion of selectivity were generally partial, often very 
ligand-specific and thus unpredictable.[39,54] Taking into 
account the best selectivities obtained so far in the Friedel-
Crafts alkylation of α,β-unsaturated 2-acyl imidazole 8, we 
synthesized the mirror image of ODN1, ODN4, using L-
nucleotide phosphoramidites. As expected, the use of the left-
handed L-d(TCAGGGCCCTGA)2 ODN4 sequence in the 
presence of the L3/Cu(II) complex afforded the opposite 
enantiomer with the exact the same enantioselectivity than 
the one obtained with ODN1 (Figure 12).[21] The method was 
also validated on the conjugate addition of dimethyl malonate 
and nitromethane, thus showcasing the generality of the 
method.  
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 Figure 12. Mirror image DNA-based asymmetric catalysis. 
We later applied this concept to short double-stranded 
RNA sequences,[55] which are known to adopt a different 
helical shape (A-form helix) with a large and shallow minor 
groove and a deeper and tighter major groove. Although the 
enantioselectivities achieved were lower than the ones 
obtained with DNA, we found that the GC rich 16-mer ORN1, 
L-(CAGUCAGUACUGACUG)2, provided the best selectivities 
with up to 54% ee and an expected inversion of selectivity 
depending on the D or L nature of the sequence (Figure 13). 
 
Figure 13. RNA-based asymmetric Friedel-Crafts alkylation. [ORN1 
L-(CAGUCAGUACUGACUG)2]. 
Achieving sequence-specificity was another challenge we 
decided to tackle. Hence, instead of evaluating the sequence 
dependency of a given reaction, we envisioned to design 
sequence-specific catalysts. The well-known minor groove 
binder Hoechst-33258, recognized for its strong affinity for 
AT-rich regions of DNA, was selected and modified to 
incorporate a Cu(II) binding site (Figure 14).[56] 
 
Figure 14. DNA-based asymmetric Friedel-Crafts alkylation with minor 
groove-binding ligands. [ODN6: 5'-d(CGAATTCGTT TTCGAATTCG)-3', 
ODN7: 5'-d(CGTATACGTTTTCGTATACG)-3']. 
Among all the ligands that were synthesized and 
evaluated in the Cu(II)-catalysed Friedel-Crafts alkylation of 
α,β-unsaturated 2-acyl imidazole 8 with 5-methoxyindole 32, 
ligand L5 provided the best selectivities (up of 47% ee with 
ct-DNA). Although moderate, higher selectivities were 
obtained with the ligand having the highest binding affinity 
with DNA, thus reinforcing a possible correlation between 
affinity and selectivity. 
Sequence specific targeting of 
DNA was also at the centre of the 
recent work published by Qiao and 
co-workers.[54] A four unit pyrrole-
polyamide groove binder known for 
its high affinity toward DNA was 
selected and covalently modified 
with a 4,4′-dimethyl-2,2′-bipyridine 
(L6, Figure 15). 
 
 
 
 
 
Figure 15. DNA-based asymmetric Friedel-Crafts alkylation using pyrrole-
polyamide L6. 
The Cu(II)-catalysed Friedel-Crafts alkylation of 
α,β-unsaturated 2-acyl imidazole 8 with 5-methoxyindole was 
again selected as a model reaction. A screening of both self-
complementary AT and GC-rich oligonucleotides identified 
ODN9, d(TCGGGGCCCCGA)2, as the lead sequence (up to 
48% ee). Circular dichroism spectra and singular value 
decomposition analyses suggested that different binding 
modes could co-exist depending on the nature of the 
sequence therefore affecting the enantioselectivity. It is worth 
pointing that most asymmetric Diels-Alder reactions reported 
in the literature involving a Cu-ligand complex bound to a 
synthetic ds-DNA through a supramolecular approach were 
run on α,β-unsaturated 2-acyl pyridine 11. A notable 
exception was recently described by Hennecke and co-
workers who used synthetic DNA hairpins to catalyse a Diels-
Alder between cyclopentadiene and α,β-unsaturated 2-acyl 
imidazole 8.[57] 
 
2.2.2 Covalent approach  
 
The anchoring strategy used to link the transition metal 
complex to DNA is a critical parameter that influences the 
nature of the second coordination sphere provided by the bio-
scaffold. The supramolecular anchoring approach of a 
metallic-cofactor to DNA allows a modular assembly of the 
biohybrid catalyst and permits a rapid optimization of the 
reaction conditions. In contrast, the covalent anchoring 
approach allows to specifically position the metallic co-factor 
independently of its binding affinity to DNA but requires 
multiple synthetic steps to assemble each biohybrid catalyst. 
Taking advantage of the reactivity of bifunctional platinum 
complexes towards DNA, Gjonaj and Roelfes synthesized a 
bipyridine-platinum complex and covalently attached it to 
st-DNA. After addition of Cu(NO3)2, the new DNA-based 
catalyst L7 was evaluated in the benchmark Friedel-Crafts 
alkylation of α,β-unsaturated 2-acyl imidazole 8 with 5-
methoxyindole 32 (Figure 16).[58] Although the ees were 
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slightly lower than the ones obtained with the typical 
supramolecular approach, this new biohybrid catalyst proved 
particularly robust as showcased by a series of 10 recycling 
experiments that led to no noticeable erosion of either the 
reactivity or the selectivity.  
 
Figure 16. DNA-based asymmetric Friedel-Crafts alkylation using a 
cisplatin ligand. 
Park and Sugiyama later developed various synthetic 
DNA-based hybrid catalysts containing an intrastrand 
bipyridine ligand. The latter were prepared by incorporating a 
2,2′-bipyridine-5,5′-dicarboxylic acid moiety within a specific 
13-mer (ODN11) or an auto-complementary single-strand 
29-mer (ODN14) sequence (Figure 17).[59] The modified 
13-mer oligonucleotide was then associated with a 
complementary strand containing either a G or a C 
nucleobase against the ligand and the resulting biohybrid 
catalysts were evaluated in the intramolecular Friedel-Crafts 
alkylation of acyl imidazole 36. As a general trend, the 
catalysts containing a cytosine facing the bipyridine led to 
higher selectivities (84% ee with ODN11/ODN13 and 86% ee 
with the hairpin ODN16 vs 17% ee with ODN11/ODN12). 
 
Figure 17. DNA-based asymmetric intramolecular Friedel-Crafts alkylation 
using an intrastrand bipyridine ligand. 
These results prompted the authors to investigate further 
the role of the cytosine within the catalytic pocket. Hence, 
various counter-strands incorporating a triethylene glycol 
(ODN15a) or an alkyl linker (ODN15b and ODN15c) opposite 
to cytosine were prepared and evaluated in the Diels-Alder 
reaction between both α,β-unsaturated 2-acyl imidazole 8 and 
α,β-unsaturated 2-acyl pyridine 11 and cyclopentadiene (23). 
The best results were obtained with the triethylene glycol 
linker which afforded ees ranging between 88 and 92% 
(Figure 18).[60] 
 
Figure 18. DNA metalloenzyme-based asymmetric Diels-Alder. 
 
2.2.3 Solid-Supported DNA helix  
 
The use of solid-supported DNA for asymmetric catalysis 
was first introduced by Park and Sugiyama based on a non-
covalent immobilization of DNA on ammonium-functionalized 
silica beads.[61] The method proved highly effective with 
selectivities reaching up to 94% ee in the Diels-Alder 
cycloaddition between α,β-unsaturated 2-acyl pyridine 11 and 
cyclopentadiene. Following these results, the authors also 
developed DNA-silica minerals made from cationic Mg(II) ions, 
N-trimethoxysilylpropyl-N,N,N-trimethylammonium chloride 
(TMAPS), tetraethoxysilane (TEOS) and a Cu/ligand 
complex.[62] 
Considering the crucial importance of heterogeneous 
catalysis for industrial applications, our group has also 
embarked on the development of an eco-friendly and 
recyclable biohybrid catalyst. Our approach, which relied on 
the use of commercially available cellulose-supported (CS) 
DNA in conjunction with a Cu(II)/L3 complex, led to high 
levels of selectivity in both the Friedel-Crafts alkylation and 
the Michael addition on α,β-unsaturated 2-acyl imidazole 8 
(Figure 19).[63] Moreover, we demonstrated that the CS-ct-
DNA-Cu(II)/L3 biohybrid catalyst could be recycled up to 10 
times without any loss of reactivity or selectivity and even 
adapted to a single-pass continuous-flow process. 
 
Figure 19. CS-ct-DNA-based asymmetric Friedel-Crafts alkylation and 
Michael addition. 
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2.4 G-quadruplex  
2.4.1 Supramolecular approach 
 
G-Quadruplex (G4DNA) are secondary structures composed 
of four-stranded G-rich DNA sequences. The core consists of 
four guanines bases associated through Hoogsteen hydrogen 
bonds forming planar square arrangements. These structures 
are stabilized by monovalent cations (preferably K+) that sit in 
the centre and interact with eight guanines. Depending on 
their unimolecular or bimolecular nature, G4DNA are 
distinguished by their topological variety which include mainly 
parallel, anti-parallel or ‘3+1’ hybrids (Figure 20).[64–67] 
 
Figure 20. G4DNA conformations. 
Considering these different arrangements and their 
respective ability to bind to a large variety of ligands, G4DNA 
also appeared as privileged bioscaffolds for asymmetric 
catalysis.[68] In the case of G4DNA-based biohybrid catalytic 
systems, both the supramolecular and covalent anchoring 
strategies were evaluated on the benchmark Diels-Alder 
cycloaddition, the Friedel-Crafts alkylation and the Michael 
addition. 
The first example of a G4-based asymmetric catalysis 
was reported by Moses and co-workers in 2010 on the 
standard Diels-Alder cycloaddition between azachalcone 11 
and cyclopentadiene.[69] G4DNA forming sequences such as 
h-Tel d(AGGGTTAGGGTTAGGGTTAGGG) and c-Kit 
d(AGGGAGGGCGCTGGGAGGAGG) were selected and 
evaluated in the presence of Cu(II) and ligand L3. Despite an 
excellent endo/exo diastereoselectivity and high conversions 
(up to 85%), the ees were rather moderate (up to 34%). 
Nonetheless, these results demonstrated the ability of 
G4DNA to act as good chiral scaffolds. Interestingly, Li et al. 
later demonstrated that G4DNA/Cu(II) could catalyse the 
reactions in the absence of ligand in up to 74% ee.[70] 
Moreover, the importance of the conformation was 
emphasized by the observation of an inversion of selectivity 
between parallel and anti-parallel G-quadruplexes. This 
reversal of selectivity was also observed with h-tel-Cu(II) in 
the presence of different alkali metal ions (Figure 21).[71] 
Hence, the enantioselectivity could be switched from (−) 58% 
to (+) 67% by simply changing the nature  
of the alkali metal ion form Na+ to K+. This inversion was 
attributed to a structural transformation from an antiparallel to 
a hybrid-type G-quadruplex structure.[72]  
The same group also prepared a terpyridine L8/Cu(II) 
complex having a high affinity to h-tel (Figure 21). The 
resulting biohybrid catalyst induced a 73-fold rate acceleration 
compared to L8 and ees up to 99%.[73] 
 
Figure 21. h-Tel G4DNA-catalysed asymmetric Diels-Alder. 
The importance of the conformation of the G4DNA was 
also confirmed in both the Friedel-Crafts alkylation[74] and the 
Michael addition.[75] Hence, the selectivity outcome of a given 
reaction can easily be set by fine-tuning the conditions 
(choice of the alkali metal ions, the ligands, the co-solvents…). 
On the down side, the ees obtained with G4DNA catalysts 
never exceeded 75%, far below the selectivities generally 
obtained in the field.  
In order to improve the performances of the G4DNA, a 
covalent anchoring strategy was also evaluated, thus 
circumventing the issues related with the binding affinity of 
the ligand.  
 
2.4.2 Covalent approach  
 
The covalent positioning of a bipyridine ligand into the 
G4DNA was first reported by Jäschke and co-workers.[76] 
New G4DNA biohybrid catalysts were obtained by covalently 
attaching a L3/Cu(II) complex via different linkers of varying 
length. The evaluation of these new G4DNA catalysts on the 
asymmetric Michael addition of dimethyl malonate on α,β-
unsaturated 2-acyl imidazole 8 revealed the importance of the 
positioning of the ligand, the length of the linker and the 
topology of the G4DNA. Interestingly, a stunning inversion of 
the selectivity was observed when using ODN17, which 
carries the modification at position 12 compared to ODN18 
which bears the exact same ligand at position 10 (Figure 22). 
Also worth pointing out is the catalyst recyclability, which was 
later demonstrated by reusing the catalyst over 10 times 
without any erosion of the selectivity.[77]  
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Figure 22. G4DNA-based asymmetric Michael addition through a covalent 
modification. 
3. Peptide and Protein-based asymmetric catalysis 
The design of artificial metalloenzymes incorporating a 
synthetic transition-metal catalyst into a protein-binding site 
also represents an emerging approach to engineer biohybrid 
catalysts. Similar to DNA-based biohybrid catalysts, covalent, 
dative, or non-covalent anchoring strategies can be applied to 
polypeptidic scaffolds. Artificial metalloproteins and artificial 
metalloenzymes have attracted a tremendous amount of 
attention over the last two decades and their design and 
catalytic activity have been depicted in several excellent 
reviews.[37,38,78-86] While our intention is to highlight the pivotal 
role played by α,β-unsaturated-2-acyl-imidazole 8 in the 
context of peptide and protein-based asymmetric catalysis, 
we owe to mention the important role played by acylpyridines 
in the development of peptide- and protein-catalysed 
asymmetric Diels-Alder reactions. Based on their earlier 
studies on the Lewis acid-catalysed Diels-Alder reaction in 
water between α,β-unsaturated-2-acyl-pyridine 11 and 
cyclopentadiene,[87,88] Engberts and co-workers reported for 
the first time the use of a hybrid complex capable of 
promoting a Diels-Alder reaction with up to 74% ee for the 
major endo isomer.[89,90] Following these results, Reetz and 
co-workers developed a phtalocyanine-copper complex 
capable of interacting with various albumin proteins to 
promote the Diels-Alder between acyl pyridine 11 and 
cyclopentadiene to afford the corresponding Diels-Alder endo 
product in up to 98% ee.[91] Interestingly, the experiment run 
with 1,3-diphenylprop-2-en-1-one in place of 11 led to only 
5% yield and 56 % ee thus demonstrating the positive 
influence of the bidentate ligand. This reaction has since been 
frequently used as a model reaction to evaluate new 
biohybrid scafflods in the context of asymmetric Diels-Alder 
reactions in water.[36,92-99] 
3.1 Artificial metalloenzymes  
Roelfes et al. selected the bovine Pancreatic Polypeptide 
bPP,[100,101] a 36 residue polypeptide hormone as a new 
biohybrid scaffold.[102] The natural peptidic hormone was 
truncated to 31 residues and grafted at the Tyr7 position with 
an  
 
Figure 23. Bovine Pancreatic Polypeptide bPP as scaffold for asymmetric 
transformations. 
active site by introducing a non-proteinogenic amino acid 
capable of binding a Cu(II) ion. The bPP variants were 
evaluated in the Cu(II)-catalysed Diels-Alder and Michael 
addition with α,β-unsaturated substrates 8 and 11 (Figure 23). 
The results showed that peptides containing 
L-3-pyridylalanine led to good enantioselectivities on both the 
Diels-Alder (up to 83% ee) and the Michael addition (up to 
86% ee). 
While this latter biohybrid catalyst was obtained by solid 
phase synthesis, the same group reported a few years later 
the in vivo incorporation of a metal-binding non-proteinogenic 
amino acid into the transcription factor Lactoccocal multidrug 
resistance Regulator (LmrR).[103] The in-vivo incorporation 
enabled the generation of LmrR mutant variants that permit a 
rapid optimization and a precise positioning of the bipyridine 
ligand (BpyAla) inside the LmrR. Application of these artificial 
metalloenzymes in the catalytic enantioselective Friedel-
Crafts alkylation of α,β-unsaturated acyl imidazole 8 with 
various  
indoles led to ees up to 83% and paved the way for directed 
evolution of artificial metalloenzymes 
The concept was later extended to three other proteins 
(QacR, CgmR and RamR) belonging to the TetR family of 
Multidrug Resistance Regulators.[104] Among them, one QacR 
mutant induced up to 94% ee in the Cu(II)-catalysed 
enantioselective Friedel-Crafts alkylation with a reverse of 
selectivity compared to other mutants including LmrR-based 
artificial metalloenzymes (Figure 24). 
Interestingly, when applied to the conjugate addition of 
water, the N-methyl-2-imidazolyl moiety was found to be not 
compatible with the active site of the LmrR artificial 
metalloenzyme whereas the hydration of α,β-unsaturated acyl 
pyridine 11 was achieved with up to 84% ee.[105] 
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Figure 24. LmrR- and QacR-based asymmetric Friedel-Crafts alkylation. 
The supramolecular assembly of an LmrR-based artificial 
metalloenzyme was also envisioned by combining a LmrR 
variant with a Cu(II) complex of phenanthroline ligand L4 
(Figure 25).[106] The rationale behind the study was based on 
the ability of planar aromatic ligands to bind to the LmrR 
hydrophobic pocket. The supramolecular approach proved to 
be superior to the covalent approach with ees up to 94% in 
the Cu(II)-catalysed enantioselective Friedel-Crafts alkylation. 
 
Figure 25. Supramolecular approach for the LmrR-based asymmetric 
Friedel-Crafts alkylation. 
These results prompted the authors to design a metal 
regulated LmrR-based artificial metalloenzyme combining 
both supramolecular and covalent anchoring strategies. The 
catalytic site was composed of the Cu(II)/L4 ligand described 
above, while the regulatory site was introduced covalently by 
standard site directed mutagenesis technique[92] resulting in 
the formation of a dimeric protein containing two metal 
binding moieties. (Figure 26).[107] 
 
 
 
 
 
Figure 26. Metal ion regulated LmrR-based asymmetric Friedel-Crafts 
alkylation. 
In the absence of Fe2+ ions, the 2-2’-bipyridine ligand 
covalently linked to LmrR binds to the catalytically active 
Cu(II)/L4 complex and deactivates the artificial 
metalloenzyme. The addition of Fe2+ ions traps the 2-2’-
bipyridine ligands and frees the active Cu2+ complex, which 
subsequently reactivates the catalyst. Hence, when applied to 
the Friedel-Crafts alkylation between α,β-unsaturated acyl 
imidazole 8 and 2-methyl indole, selectivities up to 88% ee 
were obtained thus demonstrating the synthetic potential of 
programmable artificial biohybrid catalysts.  
3.2 Peptide  
Recently, Hermann and co-workers identified cyclic peptides 
as a novel metallopeptide design containing only natural 
amino acids. The peptide scaffold was assembled by solid-
phase peptide synthesis and cyclized by an intramolecular 
disulfide linkage between cysteines at the N- and C-terminus. 
To determine the importance of a particular residue, a small 
library of 15 cyclic nonapeptides was synthesized and 
optimized using the alanine scanning technique.[108] The 
ability of the histidine to complex Cu2+ ions allowed to avoid 
the use of additional binding ligands. 
These peptides were first evaluated on the Cu(II)-
catalysed Diels-Alder cycloaddition, which led to the selection 
of shorter peptides that were ultimately used in the 
asymmetric Cu(II)-catalysed Friedel-Crafts alkylation. 
Interestingly, the truncated hexapeptide CGIARC afforded the 
highest selectivities with ees up to 99% in the Diels-Alder 
cycloaddition and 86% in the Friedel-Crafts alkylation 
(Figure 27).  
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Figure 27. Cyclic peptide-based asymmetric Diels-Alder and Friedel-Crafts 
alkylation. 
 
4. Conclusion 
Biohybrid catalysis has emerged recently as a particularly 
powerful tool for the enantioselective synthesis of chiral 
building blocks and α,β-unsaturated acyl imidazoles have 
undoubtedly been a key to this success. Indeed, these 
substrates have not only been found to be highly versatile, 
they were also shown to exhibit interesting reactivity patterns, 
a high compatibility with a large variety of bioscaffolds and 
are easily post-transformed. While various highly 
enantioselective C−C and C−O bond forming reactions have 
been unveiled, the use of α,β-unsaturated acyl imidazoles in 
the context of asymmetric biohybrid catalysis is clearly still in 
its infancy and a plethora of new reactions are expected in 
the years to come. 
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